Background: Variations in the incidence of cancer can be influenced by diet and specific lifestyles. In the last years, diet has been evaluated as an important factor in the development of ovarian cancer, even though the results have not been consistent. Dietary factors related to the risk of ovarian cancer in Mexican women were evaluated.
Methods: A case-control study in Mexico City was done during 1995-1997 in a social security hospital, evaluating 84 new cases of ovarian cancer and 629 controls. A validated questionnaire with 116 items about the frequency and type of food intake was used. The analysis of nutrients was done with the residual method adjusted for total energy intake and other predictor variables through logistic regression methods. Also, partition models estimated the total caloric intake for other sources.
Results: The nutrients negatively associated with ovarian cancer in the highest versus the lowest tertile were retinol (OR 0.52; p for trend = 0.03) and vitamin D (OR 0.43; 95% CI 0.23-0.80; p = 0.01; residual model). Additionally, carbohydrates were positively associated (partition model: OR 1.08; 95% CI 1.00-1.15), and tortilla intake did not show an association with ovarian cancer (OR 0.96; 95% CI 0.78-1.17).
Conclusions: The diet of the Mexican population is rich in carbohydrates; in Mexico corn intake is the main energy source. On the other hand, vitamins such as retinol and vitamin D were shown to be associated with this neoplasm in a protective way; nevertheless, further studies are necessary to allow us to corroborate our results. This is the first attempt in our country that relates the Mexican diet to ovarian cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000063814 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: this retrospective study aimed to evaluate the impact of BRCA mutational status on the outcomes of patients with advanced ovarian cancer treated with either primary debulking surgery (PDS) or neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS). Material and a total of 79 patients with stage III-IV ovarian cancer treated at Elias Emergency University Hospital between January 2014 and March 2024 were included. Patients received either PDS followed by chemotherapy or NACT-IDS.
View Article and Find Full Text PDFParaneoplastic cerebellar degeneration - raising awareness for early diagnosis.
Neurol Neurochir Pol
January 2024
Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland.
Advancements in pseudouridine modifying enzyme and cancer.
Front Cell Dev Biol
December 2024
Department of Oncology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Pseudouridine (Ψ) is a post-transcriptional modifier of RNA, often referred to as the 'fifth nucleotide' owing to its regulatory role in various biological functions as well as because of its significant involvement in the pathogenesis of human cancer. In recent years, research has revealed various Ψ modifications in different RNA types, including messenger RNA, transfer RNA, ribosomal RNA, small nuclear RNA, and long noncoding RNA. Pseudouridylation can significantly alter RNA structure and thermodynamic stability, as the Ψ-adenine (A) base pair is more stable than the typical uridine (U)-A base pair is due to its structural similarity to adenine.
View Article and Find Full Text PDFDurvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.
EClinicalMedicine
January 2025
Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
Background: Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in many cancers. We sought to determine the objective response rate of combination durvalumab (D) plus tremelimumab (TM) in parallel cohorts of patients with carefully selected rare cancer types in which these agents had not previously been evaluated in phase II trials and for which there was clinical or biological rationale for dual immune checkpoint inhibitor therapy to be active.
Methods: We designed a multi-centre, non-blinded, open-label phase II basket trial with each of the following 8 rare cancers considered a separate phase II trial: salivary carcinoma, carcinoma of unknown primary (CUP) with tumour infiltrating lymphocytes and/or expressing PD-L1, mucosal melanoma, acral melanoma, osteosarcoma, undifferentiated pleomorphic sarcoma, clear cell carcinoma of the ovary (CCCO) or squamous cell carcinoma of the anal canal (SCCA).
BET inhibitor JQ1 induces apoptosis of ovarian and endometrial endometrioid carcinoma cells by downregulating .
Oncol Lett
March 2025
Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Although ovarian endometrioid carcinoma (OEC), frequently associated with endometrial endometrioid carcinoma (EEC), is often diagnosed at an early stage, the prognosis remains poor. The development of new, effective drugs to target these cancers is highly desirable. The bromodomain and extra-terminal domain (BET) family proteins serve a role in regulating transcription by recognizing histone acetylation, which is implicated in several types of cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!